Publications by authors named "T Pressiani"
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Oncologist
October 2024
Article Synopsis
- In the TOPAZ-1 trial, patients with biliary tract cancers (BTC) who had recurrence within 6 months of surgery were excluded, which often happens in practice. This study looked into the effectiveness of cisplatin-gemcitabine-durvalumab (CGD) in patients who did experience early recurrence.
- The study enrolled 178 BTC patients who had surgery and then underwent treatment with CGD after experiencing either early or late disease recurrence. Key goals were to measure overall survival (OS) and progression-free survival (PFS).
- Results showed no significant differences in OS and PFS between early and late relapse groups, suggesting CGD is effective regardless of when the cancer
Article Synopsis
- Biliary tract cancers (BTCs) have an immune system that doesn't respond well to standard PD-1/PD-L1 inhibitors, but adding bevacizumab to chemotherapy may enhance immune responses.
- A phase II study involving 162 patients evaluated the effects of adding bevacizumab to atezolizumab and standard chemotherapy (cisplatin and gemcitabine), focusing on progression-free survival (PFS) as the main outcome.
- Results showed that the PFS was slightly better for patients receiving bevacizumab (8.3 months) compared to placebo (7.9 months), but overall survival (OS) was similar in both groups, indicating a modest benefit in PFS without an impact on OS. *
Article Synopsis
- The study investigates the impact of hepatic functional reserve and tumor progression on overall survival in patients with hepatocellular carcinoma (HCC) undergoing combination immunotherapy with atezolizumab and bevacizumab.
- Out of 571 patients analyzed, a significant portion developed tumor progression, while a smaller group experienced hepatic decompensation, both of which greatly affected survival outcomes.
- Key predictors of poor survival included hepatic decompensation, advanced tumor progression, and specific baseline liver function metrics, with effective antiviral treatment showing potential protective effects against decompensation in patients with viral causes of HCC.
Importance: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated.
Objective: To evaluate the association of immune checkpoint inhibitor (ICI)-based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction.
Design, Setting, And Participants: This retrospective, multicenter, international clinical case series examined data of patients with CP-B with uHCC who were receiving first-line ICI-based regimens from September 2017 to December 2022 whose data were extracted from an international consortium and compared with a cohort of patients with CP-B receiving BSC.
Background: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a global multicenter retrospective analysis of its first-line treatment outcomes.
Methods: We included patients with unresectable, locally advanced, or metastatic BTC treated with durvalumab, gemcitabine, and cisplatin at 39 sites in 11 countries (Europe, the United States, and Asia).